ASSESSMENT OF RISK FORM

TO BE COMPLETED FOR ANY DRUG BEING CONSIDERED FOR CONTAINMENT STRATEGIES THAT DIFFER FROM FULL NIOSH RECOMMENDATIONS, AS DEFINED IN USP GENERAL CHAPTER <800> HAZARDOUS DRUGS-HANDLING IN HEALTHCARE SETTINGS.

**Drug Name:**
- Tablet / Capsule
- Oral Liquid (commercial)
- Compounded liquid
- Pre-filled syringe
- Solution/powder for injection
- Other:

**Dosage Form:**
- Oral Liquid (commercial)
- Compounded liquid
- Pre-filled syringe
- Solution/powder for injection
- Other:

**NIOSH Category:**
- Table 1: Antineoplastic Drugs that only require packaging or counting
- Table 2: Non-antineoplastic Drugs
- Table 3: Reproductive Toxin Drugs

**Description of Packaging:**
- Final dosage form, ready for dispensing directly to patient (*i.e.*, unit dose, unit-of-use)
- Bottle of [tablet/capsule/liquid] to be repackaged
- Other:

**Description of Required Manipulation:**
- None (product available in ready-to-dispense package)
- Repackaging only (e.g. counting; transfer container)
- Other:

**Risk of Exposure:**
- Skin contact
- Ingestion
- Inhalation
- Injection
- Other (specify):

**Alternative Containment Strategies and/or Work Practice**

- [**Engineering Control** (*i.e.*, BSC, containment isolators, CSTDs, temporary designated prep. area)]
- [**Administrative Control** (*i.e.*, educational materials, acknowledgement form, training)]
- [**PPE Strategies** (*i.e.*, gloves, gowns, booties, head cover, face shield, eye protection, respirators)]

**Recommendation**
- Follow all containment requirements (as per USP<800>)
- Follow alternative containment strategies documented above

---

**Important note:** The information and materials provided on these documents are intended solely for healthcare professionals seeking guidance on factors to consider in assessing risks associated with drug therapies and treatments. Any individual accessing this information should seek the counsel of their facility or employer prior to use or implementation of any information in this document. The user of this information agrees to release and hold harmless HOPA and its agents from any liability arising from use of this information.

References: